Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
S Zhou, L Xie, C Zhou, L Wang, J Chen… - Clinical and …, 2023 - Wiley Online Library
Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
[HTML][HTML] Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy …
S Zhou, L Xie, C Zhou, L Wang, J Chen… - Clinical and …, 2023 - ncbi.nlm.nih.gov
Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.
S Zhou, L Xie, C Zhou, L Wang, J Chen… - Clinical and …, 2023 - europepmc.org
Keverprazan, a novel potassium-competitive acid blocker, was approved for treating acid-
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
S Zhou, L Xie, Z Chen, L Wang, J Chen… - Clinical and …, 2023 - search.proquest.com
Keverprazan, a novel potassium-competitive acid blocker, was approved for treating acid-
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
Keverprazan, a novel potassium‐competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.
S Zhou, L Xie, C Zhou, L Wang… - CTS: Clinical & …, 2023 - search.ebscohost.com
Keverprazan, a novel potassium‐competitive acid blocker, was approved for treating acid‐
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
Keverprazan, a novel potassium-competitive acid blocker: Multiple oral doses safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects
S Zhou, L Xie, C Zhou, L Wang, J Chen, S Ding, B Zhu… - 2023 - pubmed.ncbi.nlm.nih.gov
Keverprazan, a novel potassium-competitive acid blocker, was approved for treating acid-
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …
related diseases. This study aimed to analyze the safety, pharmacokinetics (PKs) and …